Discussion of Unapproved Uses the Accredited Provider will require that presenters disclose when a product is not approved in the United States for the use under discussion.
Discussion of Unapproved Uses. The Accredited Provider will require that activity faculty acknowledge their obligation to disclose to the audience when a product is not approved (“off-label”) or for investigational purposes in the United States for the use under discussion.
Discussion of Unapproved Uses. Meaningful disclosure is required when a product is not approved in the United States for the use under discussion.
Discussion of Unapproved Uses. Sponsor will require that presenter disclose when a product is not approved in the United ‘States for use under discussion.
Discussion of Unapproved Uses. Provider represents and warrants that if an unlabeled (unapproved) use of a commercial product, or an investigational use not yet approved for any purpose by the FDA, is discussed during the educational activity, Provider will require disclosure that the product is not labeled for the use under discussion or that the product is still investigational.
Discussion of Unapproved Uses. Joint Provider will require that presenter(s) disclose when a product is not approved in the United States for the use under discussion
Discussion of Unapproved Uses. The Peripheral Nerve Society will require that faculty / presenter(s) disclose when a product is not approved in the location the course is being held for the use under discussion.
Discussion of Unapproved Uses. Instructors are required to disclose when use of a product is considered off-label or investigational. Opportunities for Debate Instructors will ensure meaningful opportunities for questioning or scientific debate.
Discussion of Unapproved Uses. The Education Provider will require that if presenters discuss any product in connection with a use not approved by the U.S. Food and Drug Administration (“FDA”), the presenters disclose that the product is not approved in the United States for the use under discussion. In addition, when the information presented refers to a use, dosage or combination that is not approved by the FDA, presenters will advise the audience that they should confirm reimbursement eligibility before submitting any claim for such unapproved use, dosage or combination.
Discussion of Unapproved Uses. Speaker agrees to disclose when a product is not approved in the United States for the use under discussion.
